Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of multimodality treatment with intraoperative chemotherapy and surgical resection in (borderline) resectable pancreatic cancer
DRKS00015766Phase 2Active, not recruiting
- Sponsor
- Heidelberg University Hospital
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fluorouracil in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Heidelberg University Hospital. Primary endpoint: Safety of perioperative intraoperative chemotherapy combined with pancreaticoduodenectomy. Started Oct 2018; status: active, not recruiting.
02
Drugs
fluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on DRKS00015766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00015766.